Atopic dermatitis: dupilumab shows benefits in LIBERTY AD ADOL post hoc analyses

  • Paller AS & al.
  • Am J Clin Dermatol
  • 10 Dec 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Dupilumab is associated with improved signs, symptoms, and/or QoL in adolescent patients with moderate-to-severe atopic dermatitis (AD), according to post hoc analysis of the LIBERTY AD ADOL randomised controlled trial.

Why this matters

  • This study demonstrated benefits of dupilumab using a comprehensive evaluation combining clinician- and patient-reported outcome measures.

Key results

  • Dupilumab was associated with a higher rate of clinically meaningful improvements in AD signs, symptoms, and/or QoL compared with placebo:
    • Q2W dosing: 80.5% vs 23.5% (P<.0001>
    • Q4W: 63.1% vs 23.5% (P<.0001>
  • Results were similar vs placebo in patients with Investigator’s Global Assessment score >1 at week 16:
    • Q2W: 74.2% vs 21.7% (P<.0001>
    • Q4W: 55.1% vs 21.7% (P<.0001>

Study design

  • 251 patients ages ≥12 to
  • Funding: Sanofi; Regeneron Pharmaceuticals, Inc.

Limitations

  • Not prespecified outcomes.